Paciente com glioblastoma recorrente respondendo positivamente a dieta cetogênica combinada a álcool perílico intranasal: relato de caso e revisão da literatura Abstract Introduction Monoterpene perillyl alcohol (POH) is cytotoxic to temozolomideresistant glioma cells, regardless of its O6-methylguanine-methyltransferase (MGMT) promoter methylation status. Moreover, adherence to a ketogenic diet (KD) produced successful outcomes in preclinical and clinical studies in the glioma setting. Case Presentation A 54-year-old Caucasian man had a confirmed diagnosis of refractory glioblastoma multiforme (GBM). The immunohistochemical evaluation was negative for methylation, and failed to detect mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. In January 2016, the patient was enrolled in a clinical trial combining daily intranasal delivery of POH in combination with a KD. The KD was administered concomitantly with inhalation of POH (55 mg, 4 times a day) in an uninterrupted administration schedule for 3 months.
Introduction
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. Despite standard-of-care therapy consisting of surgery and chemoradiation therapy, the disease relapses in most patients, and the median survival is only of $ 15 months. 1 One of the major mechanisms of disease relapse in GBM patients has been attributed to the enhanced ability of poorly differentiated glioma cells to invade and infiltrate surrounding healthy tissue. 2, 3 In this aspect, the vicinity and extension of the peritumoral edema (PTE) can be useful to predict clinical outcomes in patients with a newly-diagnosed malignant glioma. 4 Epilepsy develops in around 30-50% of patients with brain tumors as a consequence of the brain swelling due to the edema accompanying the lesion. Epilepsy is a debilitating condition that causes distress and adversely affects the patient's quality of life. 5, 6 Antiepileptic drugs are commonly used to treat these patients; however, such treatments are known to exert detrimental neuropsychological effects and often interact with the therapeutic regimen, such as chemotherapeutic agents. 5, 7 Several studies have attempted to address this issue by analyzing how changes in the peritumoral tissue correlate with the onset of seizures in patients with brain tumors. Mounting evidence suggests that epileptogenesis correlates with metabolic alterations, acidosis and disruption of localized neural networks in the tumoral and peritumoral areas of the brain. 8, 9 Recent studies have suggested that consumption of a ketogenic diet (KD) might play a role in improving the outcomes of cancer patients undergoing treatment and in minimizing the frequency of epileptic episodes. [10] [11] [12] [13] The typical KD consists of Results The combination treatment was well-tolerated. The nutritional status and anthropometric measurements of the patient were measured. Adherence to the KD was confirmed by measuring the levels of ketone bodies in the urine. Throughout the treatment, a reduced frequency of seizures was observed. After three months of adherence to the treatment, the patient presented with weight loss, reduced body fat, increased water retention, and a slight increase in bone and muscle mass. A follow-up magnetic resonance imaging (MRI) scan after 3 months of treatment revealed marked reduction of the enhancing lesion. Conclusion Intranasal delivery of POH combined with concomitant adherence to a KD appeared to have a beneficial therapeutic effect in a patient with recurrent GBM. Further studies are needed to evaluate the efficacy of this therapeutic strategy in a larger cohort of treatment-refractory GBM patients. low amounts of carbohydrates, moderate amounts of protein, and high amounts of fat, aimed at stimulating fat metabolism while minimizing sugar availability. Adherence to a KD promotes a unique metabolic state resulting from elevated levels of fat-derived ketone bodies and lower levels of blood sugar, which have been correlated with improved outcomes in patients with diabetes, cancer and certain neurological disorders. 10, 14, 15 In addition, KDs have shown to reduce the frequency and severity of seizures in epileptic patients. 12, 16 In the context of cancer, KDs are presumed to counteract the Warburg effect by depriving tumor cells of glucose and improving mitochondrial activity. 10, 17 The Warburg effect is characterized by a metabolic shift from aerobic respiration toward increased glycolysis and lactate production, despite the availability of oxygen (aerobic glycolysis). 18, 19 Importantly, a major consequence of the Warburg effect is the increased cellular consumption of glucose as the main source of energy. Nevertheless, this glycolytic dependency may provide an opportunity for therapeutic intervention, based on the assumption that a reduction in glucose availability may lead to a decline in proliferation and metastatic capacity, along with increased sensitivity to cytotoxic or targeted therapies. 13, 19, 20 The shift in the ratio of ketone bodies over glucose is disadvantageous to tumor cells, since glucose-addicted cancer cells are less likely to utilize ketone bodies for energy, in contrast to normal cells, which can generate energy from either source. 21 Emerging evidence indicates that KDs may have beneficial effects in patients with malignant glioma. Results from a study in which adherence to a KD was combined with standard chemoradiotherapy in a patient with GBM have demonstrated that the patient went into complete remission while presenting with reduced blood glucose levels. 22 Subsequent case reports investigating this regimen have also shown a correlation between reduced serum glucose levels and improved therapeutic responses. 16, 17, 23 Altogether, there is intriguing evidence correlating KD and metabolic reprogramming with improved therapeutic responses to standard-of-care regimens for the treatment of patients with malignant glioma. 13, 17 We have published extensively on the antitumor effects of perillyl alcohol (POH), a naturally occurring monoterpene related to limonene, in patients with recurrent malignant glioma. A significant proportion of these patients, who had presented with tumors refractory to standard chemoradiotherapy, responded favorably to the intranasal delivery of POH. [24] [25] [26] At the molecular level, reduced glucose availability may cause endoplasmic reticulum (ER) stress, which triggers the unfolded protein response (UPR) cellular process, consisting of an interplay of antagonistic mechanisms; the low to moderate activity is cell-protective and supports chemo resistance, but more severe conditions aggravate these mechanisms to the point in which the protective efforts are abandoned, and the cell death program is induced instead. 27 As tumor cells frequently experience chronic stress conditions (due to hypoxia, hypoglycemia, acidification, oxidative stress, etc.), the protective components of their ER stress response are continuously engaged and thus, less able to neutralize additional insults that trigger the ER stress response. 28, 29 The ER stress/UPR process has been described as a potential therapeutic target in GBM, 30 and this cellular mechanism has been demonstrated to be targeted by POH in GBM cells in vitro. 31, 32 It is thus conceivable that the concerted effect of KD-induced hypoglycemia together with POH-induced responses may trigger severely aggravated ER stress, resulting in tumor cell apoptosis. 22 Based on our successful results in the clinical setting, we are now investigating whether adherence to a KD during treatment with intranasal POH can further improve the therapeutic outcomes of glioma patients. In this manuscript, we report a case study of an adult patient with recurrent glioblastoma treated with this regimen.
Palavras

Case Presentation
The present study was approved by our university (CAAE: 14613313.8.0000.5243), and was performed at the university hospital. The patient signed a written informed consent form prior to enrolling in the clinical trial combining KD with intranasal delivery of POH to assess the therapeutic efficacy of this regimen. The POH was formulated for intranasal delivery, and the preparation was supplied by a multidisciplinary laboratory of Pharmaceutical Sciences at the Universidade Federal do Rio de Janeiro, according to BR Patent Number PI 0107262-5. The KD was administered concomitantly with daily inhalation of POH for three months. Perillyl alcohol (55 mg; 0.3% v/v) was administered by inhalation 4 times a day, totaling 266.8 mg/a day.
A 54-year-old Caucasian man with no significant past medical record or family history of brain tumor or neurological disorders presented with a seizure in September 2014. A magnetic resonance imaging (MRI) brain scan revealed a regular space-occupying lesion in the left temporal-parietal lobe that was enhanced with gadolinium. The patient underwent a left temporal craniotomy with radical resection of the primary brain tumor in January 2015. Following surgery, tumor resection was confirmed by an MRI scan. The diagnosis of malignant glioma was confirmed based on complex histological features characterized by ischemic necrosis and glomeruloid microvascular proliferation.
The immunohistochemical analysis was negative for O6-methylguanine-methyltransferase (MGMT) methylation, and failed to detect mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. The patient underwent concomitant radiation therapy (59.4 Gy total) with chemotherapy (temozolomide [TMZ] 75 mg every day for 6 weeks). Then, after the conclusion of the radiation therapy, during the adjuvant phase, the patient received TMZ (150-200 mg) on a 28-day cycle with 5 days on and 23 days off for 3 cycles. In addition, the patient was treated for seizures and remained asymptomatic for eight months. At this moment (September 2015) the patient presented with complaints of dizziness and headache. A new brain MRI revealed the presence of a left temporal mass with an intense surrounding vasogenic edema. The patient underwent an additional cycle Arquivos Brasileiros de Neurocirurgia Vol. 36 No. 3/2017 of TMZ treatment, but a new MRI scan showed no reduction in the tumor lesion. The treatment was withdrawn in December 2015 because the patient was refractory to it, and presented clinical adverse effects (headache, thrombocytopenia, seizures), with an MRI scan showing no reduction in the tumoral lesion, and the patient was then considered out of therapeutic possibilities and referred to supportive (palliative) treatment. In January 2016, the patient was then enrolled in the clinical trial with KD in combination with intranasal delivery of POH.
The anthropometric and biochemical status of the patient was assessed at the time of inclusion in the study. The KD was prescribed according to the following distribution: energy (25 kcal/kg); 1.5 g/kg protein; 25% carbohydrate; and 50% lipids (cholesterol 200 mg/day; saturated fat < 7%; polyunsaturated fat < 10%, monounsaturated fat < 20%, and fibers between 20-30 g/day). 33 The levels of ketone bodies in the urine were measured (15 mg/dl), and confirmed the adherence to the KD. The KD was well-tolerated, without relevant changes in nutritional status, and no adverse symptoms were reported. The levels of ketone bodies remained between 5-15 mg/dl throughout the duration of the treatment. A complete list of the parameters analyzed before and 3 months after adherence to the KD are shown in (►Table 1).
At the end of the study, the patient presented with a weight loss of 4.36%; a decrease in body fat of 8.5%, especially in the abdominal region (↓ 10 cm waist circumference [WC]); an 8.8%-increase in water retention; and increases in bone mass (2%) and muscle mass (1%). The KD reduced the total cholesterol level, the low-density lipoprotein (LDL) cholesterol and the triglycerides levels, improving the lipid profile, although it also reduced the high-density lipoprotein (HDL) cholesterol level. The fasting blood glucose levels did not change (►Table 1).
A follow-up MRI scan conducted after 3 months of KD combined with intranasal POH therapy revealed marked reduction of the enhancing lesion (►Fig. 1) and significant clinical improvement. At three months after the completion of the therapeutic regimen, the patient was still being treated with low dose anti-seizure medication but no steroidal drugs. There were no signs of delayed toxicity or adverse events caused by the combined KD/intranasal POH treatment (data not shown).
Discussion
Herein we report a case study of a patient with recurrent GBM that has been successfully treated with KD concomitantly with POH inhalation for three months without any side effects. As a result, the patient showed tumor regression and reduced peritumoral edema, which led to an overall improvement in quality of life and lower frequency of seizures.
The severity of the peritumoral brain edema significantly influences the glioma prognosis by promoting tumor cell invasion and increasing morbidity. 4, 25 Increased diffusion of extracellular matrix components rich in proteases and tumor-derived growth factors into the peritumoral stroma during tumor progression further modifies the microenvironment and promotes neovascularization. 34 Since the reduction in the peritumoral edema in animals that were fed the KD appears to be correlated with a decrease in the expression levels of several proteins involved in malignant progression, adherence to a KD might also represent a relevant tool to halt tumor progression. 35 Our results showing a marked reduction in the peritumoral edema following our therapeutic regimen combining the administration of a KD and intranasal POH were encouraging and consistent with the literature, suggesting that the extent of the peritumoral edema may impact the overall survival in patients with GBM. 2, 36 Moreover, our results demonstrating a reduction in the frequency of seizure episodes in a patient with recurrent GBM following combined administration of the KD and intranasal POH are consistent with an increasing body of data demonstrating the value of using a KD to manage patients with intractable epilepsy. 12, 37 Importantly, seizures are often refractory to medication in patients with GBM, and can persist after surgery. 8 This is a major concern in the management of patients with GBM, as epilepsy develops in 29-49% of the patients diagnosed with brain tumors. 7, 38 In this context, tumor-related epilepsy is a condition that requires an integrated treatment approach due to the severity of the disease. 39 An adequate high-fat, low-carbohydrate, protein-based KD might be useful in the treatment and management of brain tumors because it appears to interfere with key epileptogenic mechanisms involving changes in pH, neurotransmitters, ion levels, and in the expression of voltage-dependent channels and receptors in the tumoral and peritumoral brain tissues. 9, 21 Overall, the results of this study demonstrated that the KD was well-tolerated and compatible with previous clinical findings. The KD-induced hypoglycemia can potentially be an adjuvant to standard treatments, such as surgery and chemoradiation, and also possibly to novel regimens, such as intranasal POH, in the recurrence setting. 
